X.T.L. Biopharmaceuticals Accounts Payable

X.T.L. Biopharmaceuticals (XTLB) currently reports a accounts payable of $20K as of December 2025. That compares with $200K in the prior-year period — down 89.8% year over year. Use the charts on this page to explore X.T.L. Biopharmaceuticals's accounts payable history and peer comparisons.

X.T.L. Biopharmaceuticals's accounts payable decreased from $200K to $20K — a 89.8% year-over-year decrease (period ending December 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

X.T.L. Biopharmaceuticals reported $20K in accounts payable as of December 2025. That compares with $200K in the prior-year period — down 89.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $20K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for X.T.L. Biopharmaceuticals, and consider following XTLB for alerts when major investors trade the stock.

X.T.L. Biopharmaceuticals is classified in the Healthcare sector. On accounts payable, it currently shows $20K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing XTLB with unrelated industries.